Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Rapid Dose Therapeutics Corp C.DOSE

Alternate Symbol(s):  RDTCF

Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. It provides disruptive drug delivery technologies designed to improve patient outcomes. Its flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream... see more

CSE:DOSE - Post Discussion

View:
Post by lscfa on Jul 27, 2024 2:23am

Fins on sedar

 

Q ending 

Revenue

Gross profit

Margin

May 24

398,994

256,704

64.3%

Feb 24

192,652

72,460

37.6%

Nov 23

233,814

129,399

55.3%

Aug 23

353,171

243,945

69.1%

May 23

240,787

117,605

48.8%

Feb 23

217,349

28,652

13.2%

Nov 22

305,629

227,485

74.4%

Aug 22

133,554

84,874

63.6%

May 22

61,766

31,393

50.8%

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities